Ranking Pharma's Social Media Presence: Tracking a Moving Target! A conversation with Christopher Wooden, Vice President, Global Sales at Cegedim Strategic Data (CSD), about CSD's desk research that tabulated how the top 100 pharmaceutical companies rank in terms of their Social media exposure (likes, posts, tweets, followers) on two of the most important social network websites: Facebook and Twitter. Airs LIVE on Friday, January 27, 2012 11:00 AM Eastern US. More info about listening here.

Selected Content from Most Recent Issue of Pharma Marketing News

Novo Nordisk Defends Choice of Paula Deen as Diabetes Spokesperson

The Celebrity is the Message Unless you are living under a rock on the Moon, you've probably heard that Novo Nordisk has teamed up with celebrity Southern-style chef Paula Deen as a paid spokesperson. You also probably know that Deen has Type 2 diabetes and that Novo makes a drug to treat that condition and that Deen is currently taking that drug. And you must know that Novo Nordisk and Deen have taken a lot of heat -- eg, bad publicity -- about this new relationship. We also do not know if all the bad publicity has helped or hurt Novo's efforts to promote its new "Diabetes in a New Light" website, which features new, diabetes-friendly recipes from Deen and her sons, Bobby and Jamie. Considering all the bad publicity, Pharma Marketing News asked Ambre Morley, Associate Director, Product Communications, Novo Nordisk, to be a guest on Pharma Marketing Talk where she answered questions about why her company teamed up with Deen as a diabetes spokesperson. Topics include: Why Did you Chose Paula Deen? Deen Versus Hoity-Toity Bourdain Not My Mama's Meals What About Social Media, Y'all? The Celebrity Is the Message Deen Now Emphasizes Eating in Moderation Show Us the Money! SURVEY: Use of Celebrities by Pharma Order and pay for this reprint now using your credit card... ONLY $4.95 Download PDF file immediately after paying:

FDA Guidance on Responding to Unsolicited Requests for Off-Label Information

Review of The Social Media Guidelines Nobody Expected! Two days after Christmas, on December 27, 2011, while most of us were still on vacation, the FDA quietly issued "Guidance for Industry Responding to Unsolicited Requests for Off-Label Information About Prescription Drugs and Medical Devices." Section VI. of this guidance addresses responding to unsolicited requests on public forums such as the Internet. While this may not be the "social media" guidance many people were expecting, it does include guidelines for responding to unsolicited requests for off-label information encoun-tered through "emerging electronic media." This article takes a closer look at how the off-label guidelines apply to social media such as Youtube, Blogs, and Twitter. Topics include: A Bit of History Defining "Off-label" What We Expected Was This In Best Interest of Public Health Public vs. Private, Solicited vs. Unsolicited Youtube and Solicited Requests Blogger Example of "Solicited Request" Proving Solicitation is Difficult Twitter Example of "Solicited Request" Private Responses and Serving the Public Interest Sales and Marketing May be Seen, but Should NOT Be Heard From! The Burden of Responding Docket Open for Comments Legal Challenges Chart: FDA Guidance Translator Order and pay for this reprint now using your credit card... ONLY $4.95 Download PDF file immediately after paying:

PHARMA MARKETING NEWS

www.pharmamarketingnews.com
Published by VirSci Corp.
PO Box 760
281 Stanford Place
Newtown, PA 18940-0760
www.virsci.com

Each issue of Pharma Marketing News is packed with facts, opinions, and case studies based upon interviews with experts in the field of pharmaceutical marketing. Highlights of presentations from industry conferences and links to references help subscribers keep up to date on best practices and network with their peers.

Pharma Marketing News Email Addr: